Actively Recruiting
A Phase 2 Randomized Study Comparing EC-104 High- and Low-Dose Intravitreal Implants to Ozurdex for Treating Diabetic Macular Edema
Led by Eclipse Life Sciences, Inc. · Updated on 2025-01-22
75
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating the safety and effectiveness of two doses of the EC-104 intravitreal implant containing fluocinolone acetonide compared to the marketed dexamethasone intravitreal implant Ozurdex4 in people with diabetic retinopathy and center-involving diabetic macular edema. This study focuses on participants who had a less than optimal response to prior anti-VEGF therapy and were previously treated with corticosteroids without a significant increase in eye pressure. It is a Phase 2, randomized, double-masked, multicenter trial designed to compare these treatments.
CONDITIONS
Brief Title
EC-104 Intravitreal Implant for the Treatment of Diabetic Macular Edema
Research Team
F
Freddie Batalla, MBA
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
